Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.

Plain-language guide to PMID 40762050 (2026): double-blind randomized controlled trial of Glucagon and GIP (Gastric Inhibitory Polypeptide).

Key Facts

PMID: 40762050
Journal: Diabetes, obesity & metabolism
Year: 2026
Study type: Randomized Controlled Trial
Authors: Chakravarthy MV et al. (11 authors)
DOI: 10.1111/dom.70006

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Glucagon and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

The primary endpoint was change from baseline in HbA1c at W26.

Secondary endpoints included changes from baseline to W26 in fasting glucose, 7-point self-monitored blood glucose (SMBG), body weight, lipids and the occurrence of adverse events (AEs).

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Blood Glucose, Glucagon-Like Peptide-1 Receptor Agonists and Receptors, Gastrointestinal Hormone.

Author keywords: glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, glycaemic control, incretin, obesity and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and GIP (Gastric Inhibitory Polypeptide).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.

Our Notes on the Compounds

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.